Firazyr
icatibant acetate
- Strength
- 30 mg/3mL
- Form
- Injection, Solution
- Class
- Bradykinin B2 Receptor Antagonist
Takeda Pharmaceuticals America, Inc.
Not stocked by us — reference only
Listed by Eugia US LLC
| Dosage form | Injection, Solution |
|---|---|
| Route | Subcutaneous |
| Drug class | Bradykinin B2 Receptor Antagonist |
| Approval route | ANDA — approved generic |
| NDC code | 55150-351 |
| FDA application | ANDA213521 |
| RxNorm concept | 1148141 |
| Package sizes listed | 2 |
| Marketed since | August 2023 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
icatibant acetate
Takeda Pharmaceuticals America, Inc.
Not stocked by us — reference only
Alembic Pharmaceuticals Inc.
Not stocked by us — reference only
Fresenius Kabi USA, LLC
Not stocked by us — reference only
Alembic Pharmaceuticals Limited
Not stocked by us — reference only
Teva Pharmaceuticals USA, Inc.
Not stocked by us — reference only
Hikma Pharmaceuticals USA Inc.
Not stocked by us — reference only
Cipla USA Inc.
Not stocked by us — reference only
ICATIBANT
Cycle Pharmaceuticals Ltd-Uk
Not stocked by us — reference only
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.